TCM
CRVS icon

Tang Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Tang Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,301,709
Closed -$3.27M – 96
2022
Q2 		$3.27M Buy
3,301,709
+200,000
+6% +$245K 0.5% 39
2022
Q1 		$5.09M Hold
3,101,709
– – 1.02% 28
2021
Q4 		$7.47M Sell
3,101,709
-647,670
-17% -$2.51M 1.5% 18
2021
Q3 		$18.1M Buy
+3,749,379
New +$11.1M 3.77% 8

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Tang Capital Management's CRVS Position: Q3 2022 in Review

Tang Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q3 2022, closing a stake of 3,301,709 shares — an estimated $3.27M sold.

Tang Capital Management first reported a position in CRVS in Q3 2021 and held it in 4 quarters. The position peaked at $18.1M in Q3 2021. 48 funds tracked by Wall St. Rank hold CRVS as of Q3 2022.

  • Tang Capital Management reported no remaining Corvus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Tang Capital Management sold 3,301,709 Corvus Pharmaceuticals shares in Q3 2022, an estimated $3.27M.
  • Tang Capital Management first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Tang Capital Management's Corvus Pharmaceuticals position peaked at $18.1M in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2022.

Based on Tang Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.